| Literature DB >> 28674262 |
Masaki Takigawa1,2, Hirofumi Masutomi1, Yuki Kishimoto1, Yoshitomo Shimazaki1,2, Yoshitomo Hamano3, Yoshitaka Kondo1, Tomio Arai4, Jaewon Lee5, Toshihiro Ishii6, Yoshiko Mori2, Akihito Ishigami1.
Abstract
Vancomycin hydrochloride (VCM) is a glycopeptide antibiotic that is commonly used against methicillin-resistant, Gram-positive cocci despite the nephrotoxic side effects. VCM-induced nephrotoxicity has been reported in 5-28% of recipient patients. Therefore, renal failure induced by VCM has become an important clinical problem. However, the exceedingly complex mechanism of VCM-induced nephrotoxicity is not fully understood. Therefore, this study was designed to clarify time-dependent alterations of VCM-induced nephrotoxicity in mice as a step toward decreasing the risks of kidney injury associated with VCM therapy. VCM was injected intraperitoneally into mice at a dose of 400 mg/kg body weight at 24-h intervals for 3, 5, 7, and 14 d. At 24 h after the last injection, we examined histopathological alterations of the kidney as well as blood biochemistry. VCM administration resulted in a decrease of body weight and increase of kidney weight. Histological examination revealed renal damage such as dilated proximal tubules with occasional casts and interstitial fibrosis in VCM-treated mice. Furthermore, immunohistochemical staining with anti-CD10 and anti-single-stranded DNA antibodies highlighted damaged renal proximal tubules with marked dilatation as well as numerous apoptotic cells as early as day 4 of VCM-treatment. The severity of symptoms progressed until day 15. These results suggest that VCM-induced renal damage and incipient renal failure begin soon after the start of treatment and progressively worsen. This is the first report describing the time-dependence of VCM-induced nephrotoxicity in mice and depicting a model that clarifies the mechanisms of this tissue damage.Entities:
Keywords: CD10; apoptosis; kidney; nephrotoxicity; vancomycin
Mesh:
Substances:
Year: 2017 PMID: 28674262 DOI: 10.1248/bpb.b16-00932
Source DB: PubMed Journal: Biol Pharm Bull ISSN: 0918-6158 Impact factor: 2.233